Pharma wrap: No respite for Glenmark, USFDA’s warning letter on Baddi facility adds to woes

Pharma wrap: No respite for Glenmark, USFDA’s warning letter on Baddi facility adds to woes The warning letter comes at a time when the company has been struggling with high debt and lack of meaningful approvals for products that can shore-up declining US sales

No comments:

Post a Comment